Related references
Note: Only part of the references are listed.Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
Kevin R. Kelly et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
D. S. Boss et al.
ANNALS OF ONCOLOGY (2011)
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
Kosuke Tsuboi et al.
LEUKEMIA RESEARCH (2011)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines
Marc Payton et al.
CANCER RESEARCH (2010)
AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
Adedayo Oke et al.
CANCER RESEARCH (2009)
Independent prognostic factors for AML outcome
D. Grimwade et al.
Hematology-American Society of Hematology Education Program (2009)
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
Elisabeth Walsby et al.
HAEMATOLOGICA (2008)
Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase
Hitesh B. Mistry et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis
Robert W. Wilkinson et al.
CLINICAL CANCER RESEARCH (2007)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation
A Kanda et al.
ONCOGENE (2005)
High expression of Aurora-B/Aurora and Ipl1-like midbody-associated protein (AIM-1) in astrocytomas
K Araki et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Aurora kinases link chromosome segregation and cell division to cancer susceptibility
P Meraldi et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2004)
Gene expression profiling of pediatric acute myelogenous leukemia
ME Ross et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Validity and reliability of the FACT-G scale for use in the older person with cancer
J Overcash et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
Share Paper
